The global male infertility market size was US$ 3,834 million in 2021. The global male infertility market size is forecast to reach US$ 5,885 million by 2030, growing at a compound annual growth rate (CAGR) of 5.0% during the forecast period from 2022 to 2030.
The inability of a male to cause pregnancy in a fertile woman is known as male fertility. Infertility in men is caused by problems with sperm production, concentration, or transit. Male infertility is caused by a variety of illnesses, including medical issues, psychological issues, and hormone imbalances. In some situations, male infertility is caused by testicular injury, which results in the testicle's inability to generate sperm. This feature of male infertility is related to menopause (but not natural like menopause) in that the injured testicle is usually unable to regain its sperm-making potential.
Factors Influencing Market Growth
Impact Analysis of COVID-19
The COVID-19 pandemic had a negative impact on the global market. Several governments worldwide imposed a lockdown in order to curb the spread of the deadly virus. This had halted all the non-essential emergency medical procedures. As a result, various fertility clinics and hospitals had to close their services. Many other hospitals and clinics were focusing on the treatment of COVID-19 patients. This declined the demand for fertility services.
Regional Analysis
Europe had substantial growth in 2021. As a result of the availability of developed fertility facilities, raising awareness, and increasing acceptance of more costly therapy.
North America accounted for a significant market share. As a result of the rising male infertility driven by lifestyle changes like obesity and diet.
The Asia Pacific region is forecast to have lucrative growth during the forecast period. As a result of the growing elderly population and a surge in lifestyle-related disorders.
Leading Competitors
The leading prominent companies profiled in the global male infertility market are:
Scope of the Report
The global male infertility market segmentation focuses on Test, Treatment, End-User, and Region.
Segmentation based on Test
Segmentation based on Treatment
Segmentation based on End-User
Segmentation based on Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL MALE INFERTILITY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL MALE INFERTILITY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL MALE INFERTILITY MARKET, BY TEST
5.1 OVERVIEW
5.2 OXIDATIVE STRESS ANALYSIS
5.3 DNA FRAGMENTATION TECHNIQUE
5.4 MICROSCOPIC EXAMINATION
5.5 SPERM AGGLUTINATION
5.6 COMPUTER ASSISTED SEMEN ANALYSIS
5.7 SPERM PENETRATION ASSAY
5.8 OTHERS
6 GLOBAL MALE INFERTILITY MARKET, BY TREATMENT
6.1 OVERVIEW
6.2 MEDICATION
6.3 ASSISTED REPRODUCTIVE TECHNOLOGY AND VARICOCELE SURGERY
7 GLOBAL MALE INFERTILITY MARKET, BY END-USER
7.1 OVERVIEW
7.2 HOSPITALS AND CLINICS
7.3 FERTILITY CENTERS
7.4 RESEARCH INSTITUTES
7.5 OTHERS
8 GLOBAL MALE INFERTILITY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3. 1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL MALE INFERTILITY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
10 COMPANY PROFILES
10.1 ASKA PHARMACEUTICAL CO. LIMITED
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.2 ZYDUSCADILA HEALTHCARE LIMITED
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.3 ACCESS PHARMACEUTICALS, INCORPORATED
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.4 INTAS PHARMACEUTICALS LIMITED
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.5 PANTARHEI BIOSCIENCE B
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.6 CORDEX PHARMA, INCORPORATED
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.7 MERCK SERONO
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.8 HALOTECH DNA SL
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.9 SCSA DIAGNOSTICS
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.10 ANDROLOGY SOLUTIONS
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved